β€’
Mar 31

Procter & Gamble Q3 2025 Earnings Report

Procter & Gamble reported stable earnings with modest organic sales growth in Q3 FY2025.

Key Takeaways

P&G delivered steady performance despite a tough environment, with a slight increase in EPS and net income. Organic sales grew modestly, and cash flow remained strong.

Net sales reached $19.8 billion, down 2% from the prior year.

EPS and Core EPS both came in at $1.54, a 1% increase year-over-year.

Organic sales increased by 1%, driven by higher pricing.

Operating cash flow was strong at $3.7 billion, with adjusted free cash flow productivity at 75%.

Total Revenue
$19.8B
Previous year: $20.2B
-2.1%
EPS
$1.54
Previous year: $1.52
+1.3%
Organic Sales Growth
1%
0
Adj. Free Cash Flow Productivity
75%
Gross Profit
$10.1B
Previous year: $10.3B
-2.5%
Cash and Equivalents
$9.12B
Previous year: $6.83B
+33.5%
Free Cash Flow
$2.85B
Previous year: $4.54B
-37.3%
Total Assets
$123B
Previous year: $120B
+2.8%

Procter & Gamble

Procter & Gamble

Procter & Gamble Revenue by Segment

Forward Guidance

P&G expects FY2025 sales to be flat with 2% organic growth and a 6-8% increase in diluted EPS.

Positive Outlook

  • FY2025 organic sales growth projected at ~2%.
  • Core EPS growth expected at 2–4%.
  • Diluted EPS forecasted to grow 6–8% vs. FY2024.
  • Dividend payments expected to total ~$10B.
  • Share repurchases of $6–$7B planned for FY2025.

Challenges Ahead

  • $200M after-tax FX headwind anticipated.
  • $200M after-tax commodity cost impact expected.
  • Net interest income/expense to be a slight headwind.
  • Non-repeat of minor brand divestiture benefits from FY2024.
  • Potential volatility from geopolitical and macroeconomic pressures.

Revenue & Expenses

Visualization of income flow from segment revenue to net income